Download PDF
Semin Respir Crit Care Med 2008; 29(2): 132-140
DOI: 10.1055/s-2008-1063852
Published by Thieme Medical Publishers

Pneumocystis Pneumonia

Laurie C. D'Avignon1 , Christina M. Schofield1 , Duane R. Hospenthal1
  • 1Infectious Disease Service, San Antonio Military Medical Center, Fort Sam Houston, Texas
Further Information

Publication History

Publication Date:
26 March 2008 (online)

    Permissions and Reprints

ABSTRACT

Pneumocystis is an opportunistic fungus that is a major cause of morbidity and mortality in immunocompromised hosts. Despite a decline in incidence with the advent of highly active antiretroviral therapy (HAART), Pneumocystis remains the most common opportunistic infection in patients with the acquired immunodeficiency syndrome (AIDS) and is an increasing cause of disease in patients with other forms of immunosuppression. Although there have been advances in the prevention and treatment of this infection, the mortality for Pneumocystis pneumonia (PCP) in the setting of AIDS remains 10 to 20%. The mortality for patients with other forms of immunosuppression is poorly defined but may actually be higher than that reported in the setting of AIDS. The continued severity of PCP in the AIDS population, its increasing frequency in other immunosuppressed populations, and increasing evidence that normal hosts may serve as a reservoir for the organism merit continued evaluation of the epidemiology, clinical presentation, diagnosis, and treatment of this infection.

KEYWORDS

Pneumocystis - P. jiroveci - P. carinii - PCP - pneumocystosis

REFERENCES

  • 1 Steele C, Shellito J, Kolls J. Immunity against the opportunistic fungal pathogen Pneumocystis .  Med Mycol. 2005;  43 1-19
    PubMedGoogle Scholar
  • 2 Chagas C. Nova tripanosomizae humana.  Mem Inst Oswaldo Cruz. 1909;  1 159-218
    PubMedGoogle Scholar
  • 3 Stringer J R, Beard C B, Miller R F, Wakefield A E. A new name (Pneumocystis jiroveci) for Pneumocystis from humans.  Emerg Infect Dis. 2002;  8 891-896
    CrossrefPubMedGoogle Scholar
  • 4 Stringer J R. Pneumocystis .  Int J Med Microbiol. 2002;  292 391-401
    CrossrefPubMedGoogle Scholar
  • 5 Cushion M T. Pneumocystis . In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH Manual of Clinical Microbiology. 8th ed. Washington, DC; ASM Press 2003: 1712-1725
    Google Scholar
  • 6 Edman J C, Kovacs J A, Masur H, Santi D V, Elwood H J, Sogin M L. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi.  Nature. 1988;  334 519-522
    CrossrefPubMedGoogle Scholar
  • 7 Vargas S L, Hughes W T, Santolaya M E et al.. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants.  Clin Infect Dis. 2001;  32 855-861
    CrossrefPubMedGoogle Scholar
  • 8 Walzer P D. Immunological features of Pneumocystis carinii infection in humans.  Clin Diagn Lab Immunol. 1999;  6 149-155
    PubMedGoogle Scholar
  • 9 Cassanova-Cardiel L, Leibowitz M J. Presence of Pneumocystis carinii DNA in pond water.  J Eukaryot Microbiol. 1997;  44(s6) 28
    CrossrefPubMedGoogle Scholar
  • 10 Wakefield A E. DNA sequences identical to Pneumocystis carinii f. sp. Carinii and Pneumocystis carinii f. sp. Hominis in samples of air spora.  J Clin Microbiol. 1996;  34 1754-1759
    PubMedGoogle Scholar
  • 11 Icenhour C R, Rebholz S L, Collins M S, Cushion M T. Widespread occurrence of Pneumocystis carinii in commercial rat colonies detected using targeted PCR and oral swabs.  J Clin Microbiol. 2001;  39 3437-3441
    CrossrefPubMedGoogle Scholar
  • 12 Medrano F J, Montes-Cano M, Conde M et al.. Pneumocystis jirovecii in general population.  Emerg Infect Dis. 2005;  11 245-250
    PubMedGoogle Scholar
  • 13 Larsen H H, Von Listow M, Lundgren B, Hogh B, Westh H, Lundgren J. Primary Pneumocystis infection in infants hospitalized with acute respiratory tract infection.  Emerg Infect Dis. 2007;  13 66-72
    CrossrefPubMedGoogle Scholar
  • 14 Chabe M, Dei-Cas E, Creusy C et al.. Immunocompetent hosts as a reservoir of Pneumocystis organisms: histological and RT-PCR data demonstrate active replication.  Eur J Clin Microbiol Infect Dis. 2004;  23 89-97
    CrossrefPubMedGoogle Scholar
  • 15 Stringer C, Armstrong D, Rosen P P, Shottenfeld D. Pneumocystis carinii pneumonia: a cluster of eleven cases.  Ann Intern Med. 1975;  82 772-777
    PubMedGoogle Scholar
  • 16 Goesch T R, Gotz G, Stelbrinck K H et al.. Possible transfer of Pneumocystis carinii between immunodeficient patients.  Lancet. 1990;  336 627
    PubMedGoogle Scholar
  • 17 Bensousan T H, Garo B, Islam S et al.. Possible transfer of Pneumocystis carinii between kidney transplant recipients.  Lancet. 1990;  336 1066-1067
    PubMedGoogle Scholar
  • 18 Jacobs J L, Libby D M, Winters R A et al.. A cluster of Pneumocystis carinii pneumonia in adults without predisposing illnesses.  N Engl J Med. 1991;  324 246-250
    CrossrefPubMedGoogle Scholar
  • 19 Chave J, David S, Wauters J et al.. Transmission of Pneumocystis carinii from AIDS patients to other immunosuppressed patients: a cluster of Pneumocystis carinii pneumonia in renal transplant patients.  AIDS. 1991;  5 927-932
    PubMedGoogle Scholar
  • 20 Rabodonirina M, Vanhems P, Couray-targe S et al.. Molecular evidence of interhuman transmission of pneumocystis pneumonia among renal transplant recipients hospitalized with HIV infected patients.  Emerg Infect Dis. 2004;  10 1766-1773
    PubMedGoogle Scholar
  • 21 Hocker B, Wendt C, Nahimana A, Tonshoff B, Hauser P. Molecular evidence of Pneumocystis transmission in pediatric transplant unit.  Emerg Infect Dis. 2005;  11 330-332
    PubMedGoogle Scholar
  • 22 Kaplan J E, Masur H, Holmes K K. Guidelines for preventing opportunistic infections among HIV-infected persons.  MMWR Recomm Rep. 2002;  51 1-52
    PubMedGoogle Scholar
  • 23 Huang L, Stansell J D. Pulmonary complications of human immunodeficiency virus infection. In: Mason RJ, Murray JF, Broaddus VC, Nadel JA Textbook of Respiratory Medicine. 4th ed. Philadelphian, PA; Elsevier Saunders 2005: 2111-2162
    Google Scholar
  • 24 Sandhu J S, Goodman P C. Pulmonary cysts associated with Pneumocystis carinii pneumonia in patients with AIDS.  Radiology. 1989;  173 33-35
    PubMedGoogle Scholar
  • 25 Thomas C F, Limper A H. Pneumocystis pneumonia.  N Engl J Med. 2004;  350 2487-2498
    CrossrefPubMedGoogle Scholar
  • 26 Sundar K M, Rosado-Santos H R, Reimer L G, Murray K A, Michael J R. Unusual presentation of thoracic Pneumocystis carinii infection in a patient with acquired immunodeficiency syndrome.  Clin Infect Dis. 2001;  32 498-501
    CrossrefPubMedGoogle Scholar
  • 27 Mikaelsson L, Jacobsson G, Andersson R. Pneumocystis pneumonia: a retrospective study 1991-2001 in Gothenburg, Sweden.  J Infect. 2006;  53 260-265
    CrossrefPubMedGoogle Scholar
  • 28 Kovacs J A, Hiemenz J W, Macher A M et al.. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.  Ann Intern Med. 1984;  100 663-671
    PubMedGoogle Scholar
  • 29 Ng V L, Yajko D M, Hadley W K. Extrapulmonary pneumocystosis.  Clin Microbiol Rev. 1997;  10 401-418
    PubMedGoogle Scholar
  • 30 Afessa B, Green W, Chao J et al.. Pulmonary complications of HIV infection: autopsy findings.  Chest. 1998;  113 1225-1229
    CrossrefPubMedGoogle Scholar
  • 31 Walzer P D, Smulian A G. Pneumocystis species. In: Mandell GL, Bennett JE, Dolin R Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease. 6th ed. Philadelphia; Elsevier Churchill Livingstone 2005: 3080-3094
    Google Scholar
  • 32 Procop G W, Hadda S, Quinn J et al.. Detection of Pneumocystis jiroveci in respiratory specimens by four staining methods.  J Clin Microbiol. 2004;  42 3333-3335
    CrossrefPubMedGoogle Scholar
  • 33 Larsen H H, Huang L, Kovacs J A et al.. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients.  J Infect Dis. 2004;  189 1679-1683
    CrossrefPubMedGoogle Scholar
  • 34 Peterson J C, Cushion M T. Pneumocystis: not just pneumonia.  Curr Opin Microbiol. 2005;  8 393-398
    CrossrefPubMedGoogle Scholar
  • 35 Huang L, Morris A, Limper A H, Beck J M. Recent advances and future directions in Pneumocystis pneumonia (PCP).  Proc Am Thorac Soc. 2006;  3 655-664
    CrossrefPubMedGoogle Scholar
  • 36 Cruciani M, Marcai P, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1 infected patients.  Eur Respir J. 2002;  20 982-989
    CrossrefPubMedGoogle Scholar
  • 37 Kagawa F T, Kirsch C M, Yenokida G G, Levine M L. Serum lactate dehydrogenase activity in patients with AIDS and Pneumocystis carinii pneumonia.  Chest. 1988;  94 1031-1033
    CrossrefPubMedGoogle Scholar
  • 38 Zaman M K, White D A. Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia.  Am Rev Respir Dis. 1988;  137 796-800
    CrossrefPubMedGoogle Scholar
  • 39 Garay S M, Green J. Prognostic indicators in the initial presentation of Pneumocystis carinii pneumonia.  Chest. 1989;  95 769-772
    CrossrefPubMedGoogle Scholar
  • 40 Boldt M J, Bai T R. Utility of lactate dehydrogenase vs radiographic severity in the differential diagnosis of Pneumocystis carinii pneumonia.  Chest. 1997;  111 1187-1192
    CrossrefPubMedGoogle Scholar
  • 41 Skelly M, Hoffman J, Fabbri M, Holzman R S, Clarkson A B, Merali S. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia.  Lancet. 2003;  361 1267-1268
    CrossrefPubMedGoogle Scholar
  • 42 Huang L, Stansell J, Osmond D et al.. Performance of an algorithm to detect Pneumocystis carinii pneumonia in symptomatic HIV-infected persons.  Chest. 1999;  115 1025-1032
    CrossrefPubMedGoogle Scholar
  • 43 Gruden J F, Huang L, Turner J et al.. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal or nonspecific radiographic findings.  AJR Am J Roentgenol. 1997;  169 967-975
    CrossrefPubMedGoogle Scholar
  • 44 Benson C A, Kaplan J E, Masur H, Pau A, Holmes K K. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from the CDC, the NIH, and the HIV Medicine Association/Infectious Disease Society of America.  Clin Infect Dis. 2005;  40(Suppl 3) 131-235
    CrossrefPubMedGoogle Scholar
  • 45 Hughes W, Leoung G, Kramer F et al.. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.  N Engl J Med. 1993;  328 1521-1527
    CrossrefPubMedGoogle Scholar
  • 46 Safrin S, Finkelstein D M, Feinberg J et al.. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS.  Ann Intern Med. 1996;  124 792-802
    CrossrefPubMedGoogle Scholar
  • 47 Sattler F R, Cowan R, Nielsen D M, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.  Ann Intern Med. 1988;  109 280-287
    CrossrefPubMedGoogle Scholar
  • 48 Wharton J M, Coleman D L, Wofsy C B et al.. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.  Ann Intern Med. 1986;  105 37-44
    CrossrefPubMedGoogle Scholar
  • 49 Navin T R, Beard C B, Huang L et al.. Effect of mutation in Pneumocystis carinii dihydropteroate synthase gene on outcome of P. carinii pneumonia in patients with HIV-1: a prospective study.  Lancet. 2001;  358 545-549
    CrossrefPubMedGoogle Scholar
  • 50 Dworkin M S, Hanson D L, Navin T R. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States.  J Infect Dis. 2001;  183 1409-1412
    CrossrefPubMedGoogle Scholar
  • 51 Ma L, Borio L, Masur H, Kovacs J A. Pneumocystis carinii dihydropterate synthetase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use.  J Infect Dis. 1999;  180 1969-1978
    CrossrefPubMedGoogle Scholar
  • 52 Kanzanjian P, Armstrong W, Hossler P A. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients.  J Infect Dis. 2000;  182 551-557
    CrossrefPubMedGoogle Scholar
  • 53 Takahashi T, Hosoya N, Endo T. Relationship between mutations in dihydropterate synthase of Pneumocystis carinii f. sp. Hominis isolates in Japan and resistance to sulfonamide therapy.  J Clin Microbiol. 2000;  38 3161-3164
    PubMedGoogle Scholar
  • 54 Smego R A, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.  Arch Intern Med. 2001;  161 1529-1533
    CrossrefPubMedGoogle Scholar
  • 55 Klein N C, Duncanson F P, Lenox T H et al.. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial.  AIDS. 1992;  6 301-305
    CrossrefPubMedGoogle Scholar
  • 56 Toma E, Fournier S, Dumont M et al.. Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS: a randomized, double-blind pilot trial.  Clin Infect Dis. 1993;  17 178-184
    CrossrefPubMedGoogle Scholar
  • 57 Black J R, Feinberg J, Murphy R L et al.. Clindamycin and primaquine therapy for mild-to-moderate episodes of Pneumocystis carinii pneumonia in patients with AIDS: AIDS Clinical Trials Group 044.  Clin Infect Dis. 1994;  18 905-913
    PubMedGoogle Scholar
  • 58 Toma E, Thorne A, Singer J et al.. Clindamycin with primaquine vs. trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial.  Clin Infect Dis. 1998;  27 524-530
    CrossrefPubMedGoogle Scholar
  • 59 Dohn M N, Weinberg W G, Torres F A et al.. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS.  Ann Intern Med. 1994;  121 174-180
    CrossrefPubMedGoogle Scholar
  • 60 Sattler F R, Fram P, Davis R et al.. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the ACTG protocol 029/031.  J Infect Dis. 1994;  170 165-172
    CrossrefPubMedGoogle Scholar
  • 61 Soo Hoo G W, Mohsenifar Z, Meyer R D. Inhaled or intravenous pentamidine therapy for Pneumocystis carinii pneumonia in AIDS.  Ann Intern Med. 1990;  113 195-202
    PubMedGoogle Scholar
  • 62 Conte J E, Chernoff D, Feigal D W, Joseph P, McDonald C, Golden J A. Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS.  Ann Intern Med. 1990;  113 203-209
    PubMedGoogle Scholar
  • 63 Kamboj M, Weinstock D, Sepkowitz K A. Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy.  Clin Infect Dis. 2006;  42 e92-e94
    CrossrefPubMedGoogle Scholar
  • 64 Masur H, Meier P, McCutchan J A et al.. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome.  N Engl J Med. 1990;  323 1500-1504
    PubMedGoogle Scholar
  • 65 Bozzette S A, Sattler F L, Chiu J et al.. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.  N Engl J Med. 1990;  323 1451-1457
    CrossrefPubMedGoogle Scholar
  • 66 Montaner J S, Lawson L M, Levitt N, Belzberg A, Schechter M T, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis pneumonia and the acquired immunodeficiency syndrome.  Ann Intern Med. 1990;  113 14-20
    PubMedGoogle Scholar
  • 67 Nielsen T, Eeftinck-Schattenkerk J K, Jensen B N et al.. Adjunctive corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS: a randomized European multi-center open label study.  J Acquir Immune Defic Syndr. 1992;  5 726-731
    PubMedGoogle Scholar
  • 68 Briel M, Boscacci R, Furrer H, Bucher H C. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomized controlled trials.  BMC Infect Dis. 2005;  5 101-108
    CrossrefPubMedGoogle Scholar
  • 69 Hughs W T, Kuhn S, Chaudhary A. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis.  N Engl J Med. 1977;  297 1419-1426
    PubMedGoogle Scholar
  • 70 Hughes W T. Five-year absence of Pneumocystis carinii pneumonitis in a pediatric oncology center.  J Infect Dis. 1984;  150 305-306
    PubMedGoogle Scholar
  • 71 Higgins R M, Bloom S L, Hopkin J M, Morris P J. The risks and benefits of low-dose cotrimazole prophylaxis for Pneumocystis carinii pneumonia in renal transplantation.  Transplantation. 1989;  47 558-560
    PubMedGoogle Scholar
  • 72 Winston D J, Gale R P, Meyer D V, Young S L. Infectious complications of human bone marrow transplantation.  Medicine. 1979;  58 1-31
    CrossrefPubMedGoogle Scholar
  • 73 Roblot S J, Godet G, Le Moal B. Analysis of underlying diseased and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients.  Eur J Clin Microbiol Infect Dis. 2002;  21 523-531
    CrossrefPubMedGoogle Scholar
  • 74 Bozzette S A, Finklestein S A, Spector P. A randomized trial of three anti-Pneumocystis agents in patients with advanced human immunodeficiency virus infection.  N Engl J Med. 1995;  332 693-699
    CrossrefPubMedGoogle Scholar
  • 75 Dykewicz C A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients.  Clin Infect Dis. 2001;  33 139-144
    CrossrefPubMedGoogle Scholar
  • 76 Fishman J A. Prevention of infection caused by Pneumocystis carinii in transplant recipients.  Clin Infect Dis. 2001;  33 1397-1405
    CrossrefPubMedGoogle Scholar
  • 77 Worth L J, Dooley M J, Seymour J F, Mileshkin L, Slavin M A, Thursky K A. An analysis of the utilization of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital.  Br J Cancer. 2005;  92 867-872
    CrossrefPubMedGoogle Scholar
  • 78 Souza J P, Boeckh M, Gooley T A, Flowers M ED, Crawford S W. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant patients receiving dapsone prophylaxis.  Clin Infect Dis. 1999;  29 1467-1471
    CrossrefPubMedGoogle Scholar
  • 79 Vasconcelles M J, Bernardo M VP, King C, Weller E A, Antin J H. Aerosolized pentamidine as Pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and increase risk of other infections.  Biol Blood Marrow Transplant. 2000;  6 35-43
    PubMedGoogle Scholar
  • 80 Verdier R I, Fitzgerald D W, Johnson W D, Pape J W. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients.  Ann Intern Med. 2000;  132 885-888
    PubMedGoogle Scholar
  • 81 Howe R A, Spencer R C. Cotrimoxazole: rationale for re-examining its indications for use.  Drug Saf. 1996;  14 213-218
    PubMedGoogle Scholar
  • 82 Jick H, Derby L E. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim and cephalexin for uncommon serious drug toxicity.  Pharmacotherapy. 1995;  15 428-432
    PubMedGoogle Scholar
  • 83 Van der Ven A J, Vree T B, Koopmans P P, Van der Meer J W. Adverse reactions to co-trimazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis.  J Antimicrob Chemother. 1996;  37(Suppl B) 55-60
    PubMedGoogle Scholar
  • 84 Jung A C, Paauw D S. Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients.  Arch Intern Med. 1994;  154 2402-2406
    CrossrefPubMedGoogle Scholar
  • 85 Coopman S A, Johnson R A, Platt R, Stern R S. Cutaneous disease and drug reactions in HIV infection.  N Engl J Med. 1993;  328 1670-1674
    CrossrefPubMedGoogle Scholar
  • 86 Para M F, Finklestein D, Becker S, Dohn M, Walawander A, Black J R. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS clinical trials group 268.  J Acquir Immune Defic Syndr. 2000;  24 337-343
    PubMedGoogle Scholar
  • 87 Leoung G S, Stanford J F, Giordano M F. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct re-challenge for Pneumocystis carinii pneumonia prophylaxis in immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ.  J Infect Dis. 2001;  184 992-999
    CrossrefPubMedGoogle Scholar

Laurie C D'AvignonM.D. 

Infectious Disease Service, San Antonio Military Medical Center (Brooke Army Medical Center)

3851 Roger Brooke Dr., MCHE-MDI, Fort Sam Houston, TX 78234

Email: laurie.davignon@amedd.army.mil

      >